Abstract
After initial promotion of copper excretion with D-penicillamine, the effect of oral zinc sulphate (3 X 150 mg/day, loading dose; 3 X 100 mg/day, maintenance dose) in two children with clinically stable Wilson's disease was evaluated after completion of three years' treatment. The course, judged by clinical, biochemical, and histological parameters was satisfactory in both. The urinary copper concentration reverted to less than 1.26 mumol/24 hours; and the serum copper concentration decreased further during zinc sulphate treatment. In one child the rise in 24 hour urinary copper excretion observed after a challenge dose of D-penicillamine (+/- 20 mg/kg) remained constant throughout the period of observation while the liver copper content fell from 1460 micrograms/g dry weight to 890 micrograms/g dry weight. In the other patient, however, the liver copper content as well as the 24 hour urinary copper excretion increased after D-penicillamine challenge during the third year of treatment. We conclude that zinc sulphate is a low toxic and well tolerated alternative for D-penicillamine. The dosage depends, however, on individual factors not yet well understood, and we recommend restriction of its use to patients who do not tolerate D-penicillamine well. We suggest monitoring of treatment with yearly D-penicillamine challenge and a liver biopsy if liver function deteriorates.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brewer G. J., Schoomaker E. B., Leichtman D. A., Kruckeberg W. C., Brewer L. F., Meyers N. The use of pharmacological doses of zinc in the treatment of sickle cell anemia. Prog Clin Biol Res. 1977;14:241–258. [PubMed] [Google Scholar]
- Hoogenraad T. U., Koevoet R., de Ruyter Korver E. G. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol. 1979;18(3):205–211. doi: 10.1159/000115077. [DOI] [PubMed] [Google Scholar]
- Hoogenraad T. U., Van den Hamer C. J., Koevoet R., Korver E. G. Oral zinc in Wilson's disease. Lancet. 1978 Dec 9;2(8102):1262–1262. doi: 10.1016/s0140-6736(78)92141-4. [DOI] [PubMed] [Google Scholar]
- Menard M. P., McCormick C. C., Cousins R. J. Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc. J Nutr. 1981 Aug;111(8):1353–1361. doi: 10.1093/jn/111.8.1353. [DOI] [PubMed] [Google Scholar]
- Sternlieb I., Feldmann G. Effects of anticopper therapy on hepatocellular mitochondria in patients with Wilson's disease: an ultrastructural and stereological study. Gastroenterology. 1976 Sep;71(3):457–461. [PubMed] [Google Scholar]
- Sternlier I., Morell A. G., Bauer C. D., Combes B., De Bobes-Sternberg S., Schein-Berg I. H. DETECTION OF THE HETEROZYGOUS CARRIER OF THE WILSON'S DISEASE GENE. J Clin Invest. 1961 Apr;40(4):707–715. doi: 10.1172/JCI104304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strickland G. T., Blackwell R. Q., Watten R. H. Metabolic studies in Wilson's disease. Evaluation of efficacy of chelation therapy in respect to copper balance. Am J Med. 1971 Jul;51(1):31–40. doi: 10.1016/0002-9343(71)90321-4. [DOI] [PubMed] [Google Scholar]
- WALSHE J. M. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956 Oct;21(4):487–495. doi: 10.1016/0002-9343(56)90066-3. [DOI] [PubMed] [Google Scholar]
- Walshe J. M. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med. 1973 Jul;42(167):441–452. [PubMed] [Google Scholar]